Interim Report April – September 2026

In Q2 of financial year 2026/27, net sales rose 82% to SEK 157.2 million from SEK 86.4 million a year earlier. EBITDA margin improved to 19% from 10%, while gross margin was 36% versus 38%, despite SEK 15 million of receivables and inventory write-downs. No products were launched during the quarter, two were added to the pipeline, and Mellozzan launched in Turkey; the article text cuts off while describing Memprex.

Analysis

The key question is whether EBITDA improvement reflects repeatable operating leverage or temporary cost timing: gross margin remains below the year-ago level even before considering that SEK 15m of receivables and inventory write-downs may not recur. The write-downs are also a quality signal, not just an earnings adjustment—receivables raise collection risk, while inventory charges may point to forecasting or product-mix problems. The 82% sales growth is difficult to underwrite without the prior-year base, organic-versus-acquired split, and cash conversion.

Near term, the market may reward the stronger EBITDA trajectory, but the next 1–3 months hinge on evidence that sales convert to cash and gross margin stabilizes. Turkey adds an option on distribution and geographic expansion, not yet a demonstrated revenue driver; verify launch economics, regulatory status, and partner/channel exposure. The excerpt is truncated, so no conclusion is possible about Memprex’s status. Over 6–18 months, pipeline additions matter only if they translate into launches and repeat prescriptions without heavier commercial spending.

Contrarian view: investors could over-weight headline growth and treat write-downs as isolated. Conversely, if the charges are genuinely exceptional and cash collections improve, current margin weakness may understate normalized earnings potential. No company identity, valuation, cash-flow data, or full report is supplied, so a directional equity trade is not justified.

Key Decisions for Investors

• No trade on this excerpt alone; identify the issuer and review valuation, cash flow, and the complete report before sizing exposure.
• At the next disclosure, check organic sales growth, receivables aging and cash collections, inventory levels, and whether further write-downs occur; persistent deterioration would falsify the normalization case.
• Treat Turkey as a catalyst watch, not a revenue assumption: seek evidence of regulatory clearance, distribution execution, and sales contribution before underwriting it.
• Reassess after the next quarter: sustained gross-margin recovery alongside positive cash conversion would support the operating-leverage thesis; flat or falling gross margin with renewed working-capital charges would argue against it.